Transcatheter Aortic Valve Implantation for Aortic Stenosis
Transcatheter aortic valve replacement with an FDA-approved transcatheter heart valve system may be considered medically necessary for individuals with native valve aortic stenosis who have severe aortic stenosis with a calcified aortic valve, New York Heart Association Class II, III or IV heart failure symptoms, and no unicuspid or bicuspid aortic valves. Valve-in-valve replacement of a failed surgical bioprosthetic aortic valve may be considered medically necessary when the individual meets the policy's surgical risk criteria documented by at least 2 cardiovascular specialists, and use of a cerebral embolic protection device (e.g., Sentinel) during these procedures is considered investigational. The 08/13/2025 update changed the policy description regarding devices, and the policy statements are unchanged.